Powered by
ROCHESTER — OptimizeRx Corp. (NASDAQ: OPRX), the Rochester-based provider of digital health messaging for the pharmaceutical industry, has partnered with Medicom Health, a Minneapolis-based software company that creates health and …
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq:ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-lowering drugs, announced the appointment of Jay P. Shepard as a Class III …
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based cholesterol drug developer, has announced positive top-line results from the third of five pivotal Phase 3 studies (Study 3 or …
ANN ARBOR — NanoBio Corp., a clinical-stage biopharmaceutical company, announced that it has changed its corporate name to BlueWillow Biologics in conjunction with the closing of a $10 million Series …
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical developer, announced positive results from the latest test of its lead drug candidate, bempedoic acid. The Phase 3 study …
FLINT — Diplomat Pharmacy Inc. (NYSE: DPLO), the Flint-based specialty pharmacy services provider, has unveiled CastiaRx, a specialty benefit management business. CastiaRx unites the full-service pharmacy benefit manager capabilities of …
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor company developing new treatments for high cholesterol, announced positive rsults from a Phase 2 clinical study of its drug …
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq:ESPR), Monday announced the start of a Phase 3 study to assess the safety and efficacy of a combination pill containing its cholesterol-fighter, bempedoic …
FLINT — Diplomat Pharmacy Inc. (NYSE: DPLO) has acquired 8th Day Software and Consulting, LLC, and named its founder as Diplomat’s chief information officer. 8th Day Software, based in Cordova, …
ANN ARBOR — Michigan’s second event to showcase the state’s academic drug R&D activities will be held Tuesday, Oct. 10 and hosted by Wayne State University. The “Cutting Edge Drug …